A study comparing the treatment benefits of MPDL32018 used alone and used together with Avastin to Sunitinb. Benefit is being studied in patients who have advanced kidney cancer or kidney cancer which has spread to other parts of the body and has not been treated before. Acesta este un studiu de faza II, multicentric, randomizat, cu etichetă vizibilă, conceput pentru a estima eficacitatea MPDL3280A + bevacizumab şi a MPDL3280A monoterapie faţă de sunitinib la pacienţii cu RCC confirmat histologic, inoperabil, avansat local sau metastatic, care nu au beneficiat anterior de terapie sistemică nici în contextul adjuvant, nici în cel metastatic To evaluate the efficacy of MPDL3280A + bevacizumab and MPLD3280A monotherapy compared with sunitinib as measured by progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors, V...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A pilot study of trastuzumab monotherapy in patients who progressed under a previous platinum-based or 5-fluoropyrimidin-based chemotherapy in metastatic or locally advanced gastric cancer to determine the response rate (CR + PR) according to RECIST criteria

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study of MPDL3280A (ANTI PD-L1 ANTIBODY) in Patients with PD-L1-selected, High-risk Muscle-invasive Bladder Cancer after Surgery To evaluate the efficacy of adjuvant MPDL3280A treatment in patients with programmed death ligand 1 (PD L1) selected muscle invasive bladder cancer (MIBC), as measured by disease-free survival (DFS)

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized, phase 3, controlled, double-blind, parallel-group, multicenter study to evaluate the safety and efficacy of rituximab in combination with methotrexate (MTX) compared to MTX alone, in methotrexate-naïve patients with active rheumatoid arthritis 1. To determine the efficacy of rituximab in the prevention of progression in structural joint damage and to evaluate the safety of rituximab in patients with active rheumatoid arthritis initiating tr...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

MO28048 : Etude de cohorte de phase 3 évaluant la sécurité d’emploi et la tolérance de l’administration du trastuzumab par voie sous-cutanée de façon assistée standard, ou en auto-administration avec un dispositif à injection unique, chez des patientes ayant un cancer du sein HER2+ opérable. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] L’objectif de cet essai est de comparer la tolérance et la sécurité d’utilisation du trastuzumab par administration sous cutanée assistée par rapport à l’auto administration avec un dispositif d’injec...

• Pays France
• Organes Sein
• Spécialités Chirurgie, Thérapies Ciblées

An open-label, multi-centre, dose escalating, phase I/randomized phase II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD20+ malignant disease To investigate the overall response rate and safety data of RO5072759 (1000mg flat dose) given as monotherapy in patients with relapsed CD20+ indolent NHL compared with rituximab(375mg/m2) monotherapy...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy as Neoadjuvant Therapy in Patients With HER2-Positive Early Breast Cancer The primary objective of this study is to evaluate the cardiac safety of neoadjuvant treatment with the following regimens: • ddAC-->T+ PH: Dose-dense doxorubicin and cyclophosphamide (ddAC) given ev...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Hoffmann-La Roche BO20999 : Essai de phase 2 en escalade de doses évaluant la tolérance du R7159 (obinutuzumab) chez des patients ayant une tumeur maligne à CD20+. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] An Open-Label, Dose-Escalating Study to Investigate the Safety and Tolerability of R7159 Monotherapy in Patients With CD20+ Malignant Disease.

• Pays France
• Organes Leucémies chroniques, Lymphomes non hodgkinien
• Spécialités Thérapies Ciblées

An open-label, randomized 2-period crossover study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability of warfarin in combination with oseltamivir in volunteers stabilized on warfarin therapy • To investigate the effect of a 5-day treatment course with oseltamivir on the pharmacodynamics of warfarin in volunteers stabilized on warfarin

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study of a combination of Trastuzumab and Capecitabine with or without Pertuzumab in patients with HER2-positive metastatic breast cancer Studie porovnávající kombinaci Trastuzumabu a Capecitabinu podávanou s nebo bez Pertuzumabu u pacientek s HER2 pozitivním metastatickým karcinomem prsu To compare progression-free survival (PFS) between the two treatment arms based on assessments by an independent review facility (IRF).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune